Infliximab may be effective in the treatment of steroid-resistant eosinophilic fasciitis: report of three cases. | Read by QxMD (original) (raw)

Case Reports

Journal Article

Research Support, N.I.H., Extramural

Research Support, Non-U.S. Gov't

OBJECTIVE: EF is a rare fibrosing disorder that may involve skin and internal organs. Current therapies include moderate- to high-dose glucocorticoids with or without use of immunosuppressives.

METHODS: We report three cases of steroid-resistant EF in clinical practice who were treated with 3 mg/kg every 8 weeks infliximab therapy.

RESULTS: All patients noticed an improvement in their symptoms, joint contractures and skin thickening within 8 weeks of starting infliximab therapy, ultimately leading to a drug-free remission (range 1-3 years).

CONCLUSION: Based on this and other reported cases, infliximab may be beneficial in patients with steroid-resistant EF.